Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.24% | 57.06% | 56.48% | 46.13% | 63.73% |
| Total Depreciation and Amortization | -90.45% | -90.15% | -64.10% | 13.29% | -55.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 86.93% | -8.06% | 265.61% | -39.00% | -17.80% |
| Change in Net Operating Assets | 99.13% | 512.67% | -33.62% | -56.92% | -136.04% |
| Cash from Operations | 40.23% | 77.28% | 95.71% | 40.74% | 49.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -99.90% | -- |
| Total Debt Issued | -68.20% | -- | -- | -- | -- |
| Total Debt Repaid | -9,137.88% | -- | 83.81% | 51.67% | -3.10% |
| Issuance of Common Stock | -- | -- | -94.88% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 18.21% | 92.82% | -100.00% | -100.00% |
| Cash from Financing | -39.73% | 6,277.71% | -93.35% | 481.77% | 2,549.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.29% | 106.78% | -82.03% | -220.63% | 124.56% |